| Literature DB >> 35624862 |
Hien Thi Hoang1, Jae-Seok Park2, Seong-Hyeon Kim1, Ju-Young Moon3, Young-Chul Lee1,4.
Abstract
Recently, utilizing natural bioactive compounds for active ingredients in cosmetics has become a growing worldwide trend. More and more studies aim to identify the sources of herbal ingredients for applications in the pharmaceutical and cosmetic fields. Additionally, in order to optimize the safety of natural ingredients, choosing an environmentally friendly extraction method also plays an important role. In this work, an eco-friendly extraction technique for Dendropanax morbifera using microwave treatment and microwave-assisted Dendropanax morbifera extract (MA-DME) was investigated. The results indicate that higher yields of MA-DME were obtained than with conventional methods and that D. morbifera's antioxidant properties were enhanced. Moreover, we found that MA-DME exhibited extraordinary antioxidant, anti-aging, and skin-whitening activities. We suggest MA-DME as a potential cosmeceutical ingredient than could be utilized for comprehensive protection of human skin.Entities:
Keywords: Dendropanax morbifera; cosmeceutical ingredient; cosmetic applications; cytotoxicity; microwave-assisted extraction
Year: 2022 PMID: 35624862 PMCID: PMC9137482 DOI: 10.3390/antiox11050998
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1The extraction process for MA-DME.
Figure 2High-resolution extracted ion chromatograms for MA-DME: (a) positive ion mode; (b) negative ion mode.
Identified compounds in MA-DME.
| No | Compound | Formula | Ion Mode | Retention Time | Extract Mass (m/z) | Suggested Role |
|---|---|---|---|---|---|---|
| 1 | Quinic acid | C7H12O6 | – | 0.59 | 191.0558 | Astringent, anti-viral |
| 2 |
|
|
|
|
| |
| 3 | 4-O-Caffeoylquinic acid | C16H18O9 | – | 3.52 | 353.0871 | |
| 4 |
|
|
|
|
|
|
| 5 | Benzyl alcohol xylopyranosyl(1->6)glucopyranoside | C18H26O10 | – | 3.71 | 401.1437 | Tea aroma glycosidic precursor bioactivation |
|
|
|
| – |
|
| |
| + | 3.79 | 595.2663 | ||||
| 7 |
|
| – |
|
|
|
| 8 |
|
| – |
|
|
|
| 9 | 1,3-Dihydroxy-2-hydromethylanthraquinone-3-B-β-D-xylopyranose(1->6)-β-D-glucopyranoside | C16H28O14 | – | 4 | 563.1395 | N/A |
| + | 3.99 | 565.2557 | ||||
| 10 | Apiin | C16H28O14 | – | 4.09 | 563.1402 | Anxiolytic, |
| + | 4.09 | 565.1562 | ||||
| 11 | Isochaftoside | C16H28O14 | – | 4.23 | 563.1399 | Flavones |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
| |
|
|
|
| ||||
| 14 | Nelumboroside A | C27H30O16 | – | 4.57 | 609.1450 | Antioxidant |
| 15 | 3,8-Di-C-glucosylapigenin | C27H30O15 | – | 4.79 | 593.1499 | N/A |
|
|
|
|
|
|
|
|
| 17 | Terestigmine | C21H33N3O3 | – | 9.08 | 374.2436 | Cholinesterase inhibitor (treatment of cognition disorders) |
| 18 | N-(3-Methoxy-5-nitrophenyl)-2-(5-methyl-3,4-dinitro-1H-pyrazol-1-yl)acetamide | C13H12N6O8 | + | 0.56 | 381.0795 | N/A |
| 19 | Guanine | C5H5N5O | + | 1.45 | 152.0566 | Nucleobases |
| 20 | Daidzein-4′,7-diglucoside | C27H30O14 | + | 4.42 | 579.1728 | Phytoestrogen |
| 21 | Viscidulin I | C15H10O7 | + | 4.46 | 303.0502 | Inhibitor of hepatocellular carcinoma cells (protein Glypican-3) |
| 22 | Viscumneoside III | C25H26O13 | + | 4.47 | 535.1454 |
|
|
|
|
| – |
|
|
|
|
|
|
| ||||
| 24 |
|
|
|
|
|
|
| 25 | Rubianic acid (dithiooxamide) | C25H26O13 | + | 4.65 | 535.1451 | Chelating agent (detection of copper), building block in the synthesis of cyclen |
|
|
|
|
|
|
|
|
| 27 | 7-Hydroxy-1-methoxy-2-methoxyxanthone | C15H10O6 | + | 4.79 | 287.0548 | N/A |
| 28 | 6,6′-Iminobis(2,2-dimethyl-1-hexanol) | C16H35NO2 | + | 7.7 | 274.2738 | N/A |
| 29 | N~2~-[(2S,4S,5S)-5-Amino-6-cyclohexyl-4-hydroxy-2-isopropylhexanoyl]-N-[2-pyridinylmethyl)-L-isoleucinamide | C27H46N4O3 | + | 9.08 | 475.3646 | N/A |
| 30 | 4-N-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl)butanamide | C19H27N9O | + | 9.08 | 398.2415 | N/A |
| 31 | 1-Methyl-2-[(Z)-8-tetradecenyl]-4(1H)-quinolone | C24H35NO | + | 9.08 | 276.2596 | N/A |
| 32 | O-Benzyl-N-[9-(1H-imidazol-1-yl)nonanoyl]-L-seryl-N~6~-[(benzyloxy)carbonyl]-N-(2-cyclohexylethyl)-L-lysinamide) | C44H64N6O6 | + | 9.08 | 773.4956 | N/A |
Bold: Main phenolic and flavonoid compounds. Italic and Bold: Potential cosmetic compounds.
Total phenolic content and flavonoid content in MA-DME.
| Sample | Total Phenols | Total Flavonoids |
|---|---|---|
| MA-DME | 313.03 ± 3.9 | 32.37 ± 0.9 |
| Black extract 5% | 252.25 ± 6.9 | 21.04 ± 1.1 |
| Transparent extract 5% | 30.59 ± 4.2 | 0 |
Figure 3The effect of MA-DME on the viability of HaCaT cells compared with Black extract and Transparent extract for (a) 24 h, (b) 48 h. The viability of MA-DME (10 to 300 µg/mL) was measured via MTT assay, n = 3.
Figure 4The effect of MA-DME on ROS compared with Black extract and Transparent extract for (a) 24 h, (b) 48 h , n = 3.
Figure 5ABTS radical scavenging activity of MA-DME and Transparent extract.
Figure 6Tyrosinase inhibitory effects of MA-DME, Transparent extract and positive controls, n = 3.
Inhibition activity (%) of MA-DME targeting porcine pancreas elastase activity (0.4 U/mL).
| Concentration | Elastase Inhibition Ratio (%) * | ||
|---|---|---|---|
| MA-DME | Retinol | Adenosine | |
| 6.25 | 4.6 ± 2.0 | 4.6 ± 2.5 | 3.5 ± 1.4 |
| 12.5 | 6.8 ± 2.4 | 13.8 ± 1.0 | 12.2 ± 0.88 |
| 25 | 13.1 ± 1.2 | 9.04 ± 3.0 | 11.8 ± 2.9 |
| 50 | 14.9 ± 1.7 | 13.6 ± 0.90 | 14.1 ± 1.0 |
| 100 | 14.1 ± 0.60 | 13.3 ± 0.21 | 8.7 ± 1.3 |
| 200 | 15.8 ± 0.61 | 11.0 ± 1.3 | 13.0 ± 1.5 |
| 400 | 16.0 ± 0.43 | 14.5 ± 0.70 | 13.7 ± 1.6 |
(Mean ± SD) MA-DME showed high elastase inhibition activity in a specific concentration range. Additionally, MA-DME at high concentrations (100 to 400 µg/mL) showed enhanced active elastase inhibition activity compared to the effect of retinol and adenosine. Therefore, MA-DME might have a potential role in improving skin elasticity and reducing wrinkles in skin.
Figure 7Results for blue light protection effects of MA-DME.